Evaluation of iloprost in the postoperative period after liver transplantation
| ISRCTN | ISRCTN12622749 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN12622749 |
| EudraCT/CTIS number | 2010-022660-12 |
| Secondary identifying numbers | PRAISE-ZKS0006, DRKS00003514 |
- Submission date
- 14/08/2012
- Registration date
- 02/10/2012
- Last edited
- 14/07/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Injury, Occupational Diseases, Poisoning
Plain English Summary
Background and study aims
The success of a liver transplantation depends on multiple factors. A poorly functioning liver graft increases the risk of complications, severe infections, and complete organ failure. For this reason, strategies are needed to reduce the number of poorly functioning liver grafts. One such possibility is the use of prostaglandin drugs, one of these being Iloprost. Prostaglandins widen the blood vessels and they prevent the aggregation of platelets, the blood cells responsible for clotting. This should improve the blood supply (perfusion) and functioning of the transplanted liver. The aim of this study is to examine whether the continuous use of Iloprost immediately after transplantation over seven days has a positive effect on the function of the transplanted liver.
Who can participate?
Patients aged over 18 receiving a liver transplant
What does the study involve?
Participants are randomly allocated to one of two groups. In the treatment group, participants receive Iloprost continuously intravenously (into a vein) over seven days; in the control group participants receive a placebo (dummy drug) intravenously with the same dosage.
What are the possible benefits and risks of participating?
Iloprost improves the perfusion of the transplanted liver, which may improve the functioning of the liver graft and may reduce the risk of complications. The most frequent drug-related side effects are flushing, headache, nausea and vomiting. Many of these side effects are dose-dependent and may be reduced or stopped by a dosage adjustment.
Where is the study run from?
Lead centre: Jena University Hospital. Further participating centres: Charite Campus Virchow, University Medicine Berlin; University Hospital of Essen; Goethe University Hospital Frankfurt, University Hospital of Mainz, University Hospital of Heidelberg (Germany)
When is the study starting and how long is it expected to run for?
April 2012 to December 2015
Who is funding the study?
1. Astellas GmbH
2. German Federal Ministry of Education and Research
3. BayerVital GmbH
Who is the main contact?
Dr Erik Bärthel
Contact information
Scientific
University Hospital of Jena
Department of General Visceral and Vascular Surgery
Erlanger Allee 101
Jena
07740
Germany
Study information
| Study design | Prospective multi-center randomized double-blinded placebo-controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet (in German) |
| Scientific title | A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of iloprost in the early postoperative period after liver transplantation |
| Study acronym | PRAISE |
| Study hypothesis | Improved graft viability under treatment with systemically administered prostacyclin analogue iloprost. |
| Ethics approval(s) | Medical Faculty Ethics Committee, Friedrich Schiller University of Jena, 25/01/2011, ref: 2980-11/10 |
| Condition | Liver transplantation |
| Intervention | Patients of the treatment group received 1 ng/kg body weight /min iloprost, intravenous administered for 7 days post-liver transplantation, in contrast to the control (placebo) population. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Iloprost |
| Primary outcome measure | Current primary outcome measures as of 07/03/2013: Primary graft dysfunction (PDF) after liver transplantation characterized as presentation of one or more of the following criteria: 1. Alanine amino transferase / Aspartate amino transferase (ALAT or ASAT) level > 2000 lu/ml within the first 7 postoperative days 2. Bilirubin ≥ 10 mg/dl on postoperative day 7 3. INR ≥ 1.6 on postoperative day 7 or as occurrence of initial non-function (lNF) defined as graft failure originating from the graft itself, excluding hepatic artery thrombosis (HAT), biliary complication, recurrent disease or acute rejection and resulting in retransplantation or patient death within 14 days after initial LT Previous primary outcome measures: Primary graft dysfunction (PDF) after liver transplantation characterized as presentation of one or more of the following criteria: 1. Alanine amino transferase / Aspartate amino transferase (ALAT or ASAT) level > 2000 lu/ml within the first 7 postoperative days 2. Bilirubin ≥ 10 mg/dl on postoperative day 7 3. INR ≥ 1.6 on postoperative day 7 or as occurrence of initial non-function (lNF) defined as graft failure originating from the graft itself, excluding hepatic artery thrombosis (HAT) 4. Biliary complication 5. Recurrent disease or acute rejection and resulting in retransplantation or patient death within 14 days after initial LT |
| Secondary outcome measures | Current secondary outcome measures as of 07/03/2013: 1. Occurence of any infection up to day 28 after LT 2. Initial non-function (lNF) defined as graft failure originating from the graft itself, excluding hepatic artery thrombosis (HAT), biliary complication, recurrent disease or acute rejection and resulting in retransplantation or patient death within 14 days after initial LT 3. Clotting factor substitution up to day 28 after LT 4. Renal replacement therapy up to day 28 and 180 after LT 5. Liver dialysis up to day 28 and 180 after LT 6. Graft survival at day 28 and 't 80 after LT 7. Patient survival at day 28 and 180 after LT 8. Occurrence of biliary complications at day 28 and 180 after LT 9. Length of ICU stay in days up to day 180 after LT (max) 10. Length of hospital stay in days up to day 180 after LT (maximum) 11. Course of ASAT/ALAT, Quick's value/lNR, Factor V and Indocyanine green plasma disappearance rate (ICG-PDR) until day 7 after LT 12. Change in Sequential Organ Failure Assessment (SOFA)-score from day 1 to day 7 after LT Previous secondary outcome measures: 1. Initial non-function (lNF) defined as graft failure originating from the graft itself, excluding hepatic artery thrombosis (HAT), biliary complication, recurrent disease or acute rejection and resulting in retransplantation or patient death within 14 days after initial LT 2. Clotting factor substitution up to day 28 after LT 3. Renal replacement therapy up to day 28 and 180 after LT 4. Liver dialysis up to day 28 and 180 after LT 5. Graft survival at day 28 and 't 80 after LT 6. Patient survival at day 28 and 180 after LT 7. Occurrence of biliary complications at day 28 and 180 after LT 8. Length of hospital stay in days up to day 180 after LT (maximum) 9. Course of ASAT/ALAT, Quick's value/lNR, Factor V and Indocyanine green plasma disappearance rate (ICG-PDR) until day 7 after LT 10. Change in Sequential Organ Failure Assessment (SOFA)-score from day 1 to day 7 after LT |
| Overall study start date | 30/04/2012 |
| Overall study end date | 31/12/2015 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 356 randomised (900 screened, 430 with written consent) |
| Participant inclusion criteria | Current inclusion criteria as of 07/03/2013: 1. Full-size liver transplantation 2. Informed consent of the patient or legal representative 3. Aged 18 years or over Previous inclusion criteria: 1. Full-size liver transplantation 2. Informed consent of the patient or legal representative 3. Age over 18 years |
| Participant exclusion criteria | 1. Women of child-bearing potential except women with the following criteria: 1.1. Post menopausal (12 months natural amenorrhea or 6 month amenorrhea with serum FSH > 40 mlU/ml) 1.2. Sterilization 86 weeks after bilateral ovarectomy with or without hysterectomy 1.3. Using an effective method of birth control for the duration of trial: 1.3.1 Implants, injectables, combined oral contraceptives, intra-uterine device (in place for a period of at least 2 months prior to screening) and with negative serum pregnancy test 1.4. Sexual abstinence 2. Pregnancy/lactation 3. Respiratory and/or circulatory instability (noradrenaline > 1 pg/kgBWmin and FiOz > 0.6) after liver transplantation (LT) before randomization 4. Split liver transplantation/living donor related liver transplantation 5. Retransplantation 6. Receiving a multi-organ transplantation 7. Participation on other clinical trials 30 days prior to randomization 8. Known allergic reaction against trial medication 9. Conditions in which bleeding complications may be expected from the effect of lloprost on platelets 10. Severe coronary artery disease or unstable angina pectoris 11. Myocardial infarction within the past 6 months prior to baseline assessment after acceptance of donor organ 12. Acute or chronic heart failure (NYHA ll-lV) 13. Cardiac arrhythmias relevant for the prognosis 14. Suspected pulmonary artery congestion 15. Known allergy or intolerance against tacrolimus, mycophenolate mofetil, basiliximab or corticosteroids |
| Recruitment start date | 30/04/2012 |
| Recruitment end date | 31/12/2015 |
Locations
Countries of recruitment
- Germany
Study participating centre
07740
Germany
Sponsor information
University/education
Fürstengraben 1
Jena
07743
Germany
| Website | http://www.uni-jena.de/ |
|---|---|
"ROR" |
https://ror.org/05qpz1x62 |
Funders
Funder type
Hospital/treatment centre
Private sector organisation / Universities (academic only)
- Alternative name(s)
- Jena University Hospital, UKJ
- Location
- Germany
Government organisation / For-profit companies (industry)
- Alternative name(s)
- Bayer AG, Bayer Corporation, Friedr. Bayer et. comp.
- Location
- Germany
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | protocol | 29/01/2013 | Yes | No |
Editorial Notes
14/07/2016: Plain English summary added.
07/03/2013: the overall trial start date was changed from 01/04/2012 to 30/04/2012.
